1. Cell fate decision of mast cells in tumor immunotherapy. 2. Immune co-stimulatory signal OX40 and immune checkpoint PD-1 reprogram T lymphocytes in the tumor microenvironment. 3. Exploration of immune-related biomarkers for prognostic risk assessment and early diagnosis in pancreatic cancer.